Results 191 to 200 of about 4,275,355 (312)

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 3) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending January 23, 2021

open access: yes
This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 14) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending April 09, 2022

open access: yes
This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato   +27 more
wiley   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 32) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending August 13, 2022

open access: yes
This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

open access: yesArthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin   +7 more
wiley   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 31) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending August 6, 2022

open access: yes
This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Clinical Characteristics and Concordance of Anti‐MDA5 Antibodies: A Multicenter Australian Study

open access: yesArthritis Care &Research, EarlyView.
Objective In Australia, anti‐MDA5 antibodies are exclusively tested by a line immunoblot assay (LIA). The clinical concordance of an LIA‐positive anti‐MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti‐MDA5 antibodies. Methods Electronic records of a multisite cohort (patients
Syed B. Ali   +11 more
wiley   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 7) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending February 19, 2022

open access: yes
This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Home - About - Disclaimer - Privacy